Viadur is a drug owned by Ortho Mcneil Janssen Pharmaceutical Inc. It is protected by 10 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 17, 2018. Details of Viadur's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6375978 | Rate controlling membranes for controlled drug delivery devices |
Dec, 2018
(6 years ago) |
Expired
|
| US6113938 | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents |
Jul, 2018
(6 years ago) |
Expired
|
| US6124261 | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(7 years ago) |
Expired
|
| US5932547 | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(7 years ago) |
Expired
|
| US6235712 | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(7 years ago) |
Expired
|
| US5985305 | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) |
Expired
|
| US5728396 | Sustained delivery of leuprolide using an implantable system |
Jan, 2017
(7 years ago) |
Expired
|
| US6395292 | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) |
Expired
|
| US6156331 | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) |
Expired
|
| US6132420 | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
Jan, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Viadur's patents.
Latest Legal Activities on Viadur's Patents
Given below is the list of recent legal activities going on the following patents of Viadur.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical | 23 Jun, 2016 | US6395292 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Mar, 2015 | US6395292 |
| Correspondence Address Change Critical | 23 Mar, 2015 | US6395292 |
| Correspondence Address Change Critical | 26 Feb, 2008 | US6395292 |
| Change in Power of Attorney (May Include Associate POA) Critical | 31 Jan, 2008 | US6395292 |
| Correspondence Address Change Critical | 31 Jan, 2008 | US6395292 |
| Patent Issue Date Used in PTA Calculation Critical | 28 May, 2002 | US6395292 |
| Recordation of Patent Grant Mailed Critical | 28 May, 2002 | US6395292 |
| Issue Notification Mailed Critical | 10 May, 2002 | US6395292 |
| Receipt into Pubs | 02 May, 2002 | US6395292 |
US patents provide insights into the exclusivity only within the United States, but Viadur is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Viadur's family patents as well as insights into ongoing legal events on those patents.
Viadur's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Viadur's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 17, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Viadur Generic API suppliers:
Leuprolide Acetate is the generic name for the brand Viadur. 8 different companies have already filed for the generic of Viadur, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Viadur's generic
Alternative Brands for Viadur
Viadur which is used for treating prostate cancer., has several other brand drugs using the same active ingredient (Leuprolide Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie Endocrine |
| ||
| Abbvie Endocrine Inc |
| ||
| Invagen Pharms |
| ||
| Tolmar |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Leuprolide Acetate, Viadur's active ingredient. Check the complete list of approved generic manufacturers for Viadur
About Viadur
Viadur is a drug owned by Ortho Mcneil Janssen Pharmaceutical Inc. It is used for treating prostate cancer. Viadur uses Leuprolide Acetate as an active ingredient. Viadur was launched by Ortho Mcneil Janssen in 2000.
Approval Date:
Viadur was approved by FDA for market use on 03 March, 2000.
Active Ingredient:
Viadur uses Leuprolide Acetate as the active ingredient. Check out other Drugs and Companies using Leuprolide Acetate ingredient
Treatment:
Viadur is used for treating prostate cancer.
Dosage:
Viadur is available in implant form for implantation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 65MG BASE | IMPLANT | Discontinued | IMPLANTATION |